Latest News
-

AMT-130 at Four Years: Hopeful Signs, Complex Controls
⏱️ 12 min read
uniQure reports that after 4 years, people given high-dose AMT-130 continue to show signs of slower HD progression, providing hope for their recent regulatory submission. But the new analyses are nuanced. We unpack the hopeful, but complex results.
-

Switching it up: variety in the HD gene affects symptom onset
⏱️ 9 min read
Variety in the HD gene’s on switch affects when symptoms arise.
-

Measuring harmful huntingtin protein in the brain’s bath water
⏱️ 4 min read
How will we know whether HD-lowering treatments are working? New advancements in the detection of mutant huntingtin.
-

A faulty filter? Blood vessel changes in Huntington's disease
⏱️ 7 min read
New research reveals blood vessel changes that could contribute to problem in HD
-

Lighting the way: A new biomarker for Huntington’s disease
⏱️ 7 min read
A new biomarker reveals brain changes in early Huntington's disease.
-

Novel research technique suggests an antioxidant gene protects vulnerable neurons
⏱️ 8 min read
Researchers use a new technique in an HD mouse to uncover a gene, Gpx6, that is protective to vulnerable neurons.
-

Building a Better Mouse(trap): A New Model of Huntington’s Disease
⏱️ 7 min read
New mouse model gives insights into Huntington's disease
-

Taking new targets to the bank: the DNA repair protein ‘ATM’ is overactive in Huntington's disease
⏱️ 6 min read
HD causes the normally helpful protein "ATM" to get a little overzealous. Now we can look for drugs to settle it down
-

2015 Huntington's Disease Therapeutics Conference: Day 3
⏱️ 10 min read
Day 3 of updates from the annual HD Therapeutics Conference in Palm Springs
-

2015 Huntington's Disease Therapeutics Conference: Day 2
⏱️ 8 min read
Day 2 of updates from the annual HD Therapeutics Conference in Palm Springs
-

2015 Huntington's Disease Therapeutics Conference: Day 1
⏱️ 10 min read
Day 1 of updates from the annual HD Therapeutics Conference in Palm Springs
HDBuzz Trial Tracker
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
Previously featured
-
AMT-130 at Four Years: Hopeful Signs, Complex Controls
-
September 2026: This month in Huntington’s disease research
-
Studying Stutters: What 900,000 genomes teach us about growing DNA repeats
-
Highlighting Mental Health Disparities in Indigenous Communities Affected by Huntington’s Disease
-
Encouraging news from Skyhawk, as SKY-0515 Phase 1/2 data continues to hold promise
Follow HDBuzz
Sign up to our monthly email summary by entering your email address on our mailing list page.
Suggest an article
Is there something you want us to write about? Tell us about it here. We consider all suggestions but can’t promise to write content about any particular suggestion.
